Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Novartis Ireland Limited .
Filed returns
62
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Novartis Ireland Limited | Health | National Cardiovascular Health Strategy (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Health System Readiness for Advanced Cancer Therapy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) | 27 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Life Science Strategy (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | IIEA event on EU Presidency and Public Health (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | European Presidency plans for Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Attended an event for World Cancer Day (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Supporting a Health Policy Partnership Initiative for them to run a roundtable and draft a white paper with policy stakeholders. (Public policy or programme) | 26 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Roundtable policy meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Implementation of the decision to include SMA in newborn screening (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Forwarding letter to Dept of Health about access to innovative treatment for Irish patients (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Invitation to a meeting to discuss EU and Irish Cardiovascular Strategy (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | American Chamber of Commerce Event (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | AI4Ireland meeting with Oireachtas members (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | World Urticaria Day event (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Invited to the Joint Oireachtas All Party Committee on Orphan Drugs (3/12/25) (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Advocate for Life Science Strategy (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Implement the decision to include SMA screening implemented in the heelprick test for newborn babies (Matters involving public funds) | 0 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Launch of the Rare Disease National Strategy at Department of Health (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Letter to Tanaiste about access to innovative treatment for Irish patients (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | IIEA event with a panel of speakers about Developing a National Life Sciences Vision for Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Rare Disease Ireland invite to Leinster House (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Implementation of SMA onto the Heel prick test (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Timely inclusion of SMA in heel prick test (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Rare diseases conference, as an official event of the Irish EU Presidency (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | IPHA Industry meeting - engagement on trade and tariff issues (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Timely inclusion of SMA in heal prick test (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Reimbursement decision for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (Matters involving public funds) | 4 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Competitivness, government needs to be perceived as pro-innovation (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Novartis Ireland Limited | Health | Life Sciences strategy for Ireland (Public policy or programme) | 9 | On lobbying.ie |
| Sep–Dec 2024 | Novartis Ireland Limited | Health | Implementation of SMA testing into the heel prick test for newborns (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | To fund an Office of Life Sciences or Life Science Strategy (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 25 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | Access in Heart Failure (HF) & healthcare system readiness for new medicine platforms like radioligand therapies. Clinical trial attractiveness (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 6 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Health | Ensure that the healthcare system is ready for new novel treatments like radioligand therapies. Also employing guideline-directed therapy for heart failure patients. (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2023 | Novartis Ireland Limited | Health | Budget for innovative new medicines in 2024 (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2023 | Novartis Ireland Limited | Health | Expansion of newborn screening in Ireland (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2023 | Novartis Ireland Limited | Health | Ensuring the spinal muscular atrophy (SMA) is added to the heel prick test in a timely manner (Matters involving public funds) | 11 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | Concerns over Europe’s competitiveness and pro-innovation environment, regarding the revision of the EU pharmaceutical Legislation (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | Expension of the newborn screening program - adding more diseases to the heel prick test (Matters involving public funds) | 3 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | Concerns over Europe’s competitiveness regarding proposals on the revision of the EU Pharmaceutical Legislation (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | The Pharma Industry in Ireland ask for government support to reform the reimbursement process as Irish patients lagging behind EU counterparts in terms of access to medicines (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Novartis Ireland Limited | Health | Update of SmartD8 Heart of Our City Social Prescribing Project. Discussion on national Illness/wellness festival with Healthy Ireland support. Partnerships/collaborations to support the Healthcare system. (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2021 | Novartis Ireland Limited | Health | New born screening, timely access to new medicines in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Novartis Ireland Limited | Health | Expansion of Newborn Screening (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2020 | Novartis Ireland Limited | Health | Timely access to innovative new products, IP, EU Pharma Strategy (Legislation) | 1 | On lobbying.ie |
| May–Aug 2020 | Novartis Ireland Limited | Health | Supporting intellectual property incentives in rare diseases, funding for new medicines, EU Pharmaceutical Strategy, (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Novartis Ireland Limited | Health | Reimbursement of new Medicines, Intellectual Property, need for new approaches in cell & gene therapy (Matters involving public funds) | 4 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 62 | 100.0% |